Artwork

Content provided by NPR. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NPR or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The Promise and Future of Psychedelics Research

49:06
 
Share
 

Manage episode 434525570 series 48999
Content provided by NPR. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NPR or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Interest in using psychedelics for mental health treatments has taken off in recent years — but the field was just dealt a major blow on August 9, when the Food and Drug Administration rejected a bid by Lykos Therapeutics to approve the first-ever MDMA treatment for PTSD. The agency said it needed more research to show that the drug was safe and effective. The decision means that an active research community that has formed over the last few decades will likely continue as it started — more underground than above ground.
On this episode, we look at the latest on psychedelics and mental health, along with the challenges to moving the research forward. We hear stories about the battle over MDMA, new questions about whether ketamine can actually help treat depression, and a group that says it's found the solution to cluster headaches in psilocybin.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy
  continue reading

590 episodes

Artwork
iconShare
 
Manage episode 434525570 series 48999
Content provided by NPR. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NPR or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Interest in using psychedelics for mental health treatments has taken off in recent years — but the field was just dealt a major blow on August 9, when the Food and Drug Administration rejected a bid by Lykos Therapeutics to approve the first-ever MDMA treatment for PTSD. The agency said it needed more research to show that the drug was safe and effective. The decision means that an active research community that has formed over the last few decades will likely continue as it started — more underground than above ground.
On this episode, we look at the latest on psychedelics and mental health, along with the challenges to moving the research forward. We hear stories about the battle over MDMA, new questions about whether ketamine can actually help treat depression, and a group that says it's found the solution to cluster headaches in psilocybin.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy
  continue reading

590 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide